{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:08:29Z","timestamp":1790320109999,"version":"4.1.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Inflammation is closely associated with tumor development and patient prognosis. The objective of this study is to assess the prognostic value of the preoperative inflammatory indexes in pediatric hepatoblastoma patients who receive neoadjuvant chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A retrospective analysis was performed on clinical and pathological data of 199 hepatoblastoma patients who underwent hepatectomy with preoperative neoadjuvant chemotherapy from January 2015 to June 2020. The receiver operating characteristic curve was used to evaluate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) in predicting OS and EFS. Patients were grouped based on optimal cutoff values of preoperative inflammatory indexes. Survival rates were calculated using the Kaplan-Meier method, and survival outcomes were compared between groups using the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to identify independent prognostic factors, and a nomogram was constructed using R software to predict the probability of OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The receiver operating characteristic curve showed prognostic value for OS, not EFS, in preoperative inflammatory indexes. Patients were categorized into low\/high groups: SII \u2264 266.70\/higher, NLR \u2264 1.24\/higher, PLR \u2264 85.25\/higher, and SIRI \u2264 0.72\/higher. High NLR, PLR, SII, and SIRI groups had significantly lower 5-year OS than their low counterparts (all <jats:italic>p<\/jats:italic>-value &amp;lt; 0.05). The Cox analysis identified four independent prognostic factors: SIRI (HR=2.997, 95% CI: 1.119-8.031), microvascular invasion (HR=2.556, 95% CI: 1.14-5.73), the post-treatment extent of disease (POSTTEXT) staging (IV <jats:italic>vs.<\/jats:italic> I: HR=244.204, 95% CI:11.306-5274.556), and alpha-fetoprotein (&amp;gt;100 ng\/ml: HR=0.11, 95% CI: 0.032-0.381) for hepatoblastoma patients with neoadjuvant chemotherapy. High SIRI group had more patients with adverse NLR, SII, and POSTTEXT III (all <jats:italic>p<\/jats:italic>-value &amp;lt; 0.05). Independent prognostic factors led to an OS nomogram with a concordance index of 0.85 (95% CI: 0.78-0.91, <jats:italic>p<\/jats:italic>-value = 1.43e-27) and the calibration curve showed a good fit between the prediction curve and the true curve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SIRI is an independent prognostic factor of hepatoblastoma patients receiving neoadjuvant chemotherapy. The OS nomogram based on SIRI, POSTTEXT staging, MiVI, and AFP can be used to assess the prognosis of those patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1276175","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:22:37Z","timestamp":1697185357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Chen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiru","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11585","article-title":"Where do we stand with hepatoblastoma","volume":"98","author":"Schnater","year":"2003","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/children6010001","article-title":"Hepatoblastoma-the evolution of biology, surgery, and transplantation","volume":"6","author":"Lim","year":"2019","journal-title":"Children-Basel"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-008-1106-7","article-title":"Pediatric liver tumors - a pictorial review","volume":"19","author":"Jha","year":"2009","journal-title":"Eur radiology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12112","article-title":"Predictors of survival and incidence of hepatoblastoma in the paediatric population","volume":"15","author":"Allan","year":"2013","journal-title":"HPB"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29965","article-title":"Imaging of pediatric liver tumors: A COG Diagnostic Imaging Committee\/SPR Oncology Committee White Paper","author":"Schooler","year":"2023","journal-title":"Pediatr Blood cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/mot.0000000000000618","article-title":"Contemporary management of hepatoblastoma","volume":"24","author":"Hafberg","year":"2019","journal-title":"Curr Opin Organ Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30598-8","article-title":"Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration","volume":"18","author":"Meyers","year":"2017","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2015.09.023","article-title":"The (C)under-barhildren\u2019s (H)under-barepatic tumors (I)under-barnternational (C)under-barollaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model","volume":"52","author":"Czauderna","year":"2016","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30576","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Liver tumors","author":"O\u2019Neill","year":"2023","journal-title":"Pediatr Blood cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.29.3837","article-title":"Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children\u2019s Oncology Group","volume":"29","author":"Malogolowkin","year":"2011","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.14.2665","article-title":"Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children\u2019s Cancer Group and the Pediatric Oncology Group","volume":"18","author":"Ortega","year":"2000","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30895-7","article-title":"Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children\u2019s Oncology Group, multicentre, phase 3 trial","volume":"20","author":"Katzenstein","year":"2019","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2017.01.059","article-title":"Inflammation factors in hepatoblastoma and their clinical significance as diagnostic and prognostic biomarkers","volume":"52","author":"Guo","year":"2017","journal-title":"J Pediatr Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1575_21","article-title":"Immunohistochemical expression of beta-catenin in hepatoblastoma and its clinical significance","volume":"18","author":"Archana","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2016.09.070","article-title":"Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma","volume":"52","author":"Jiao","year":"2017","journal-title":"J Pediatr Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000023486","article-title":"Prognostic value of the systemic inflammation response index in human malignancy: a meta-analysis","volume":"99","author":"Wei","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal transduction targeted Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.049","article-title":"PI3K\/akt cooperates with oncogenic notch by inducing nitric oxide-dependent inflammation","volume":"22","author":"Villegas","year":"2018","journal-title":"Cell Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605530","article-title":"TNF-alpha\/NF-kappaB\/Snail pathway in cancer cell migration and invasion","volume":"102","author":"Wu","year":"2010","journal-title":"Br J cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/2326-6066.Cir-15-0313","article-title":"The complex role of neutrophils in tumor angiogenesis and metastasis","volume":"4","author":"Liang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.12.035","article-title":"SIRT1 and HIF1\u03b1 signaling in metabolism and immune responses","volume":"418","author":"Yu","year":"2018","journal-title":"Cancer letters"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.12.005","article-title":"Immune regulation by monocytes","volume":"35","author":"Murray","year":"2018","journal-title":"Semin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102310","article-title":"Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells","volume":"104","author":"Alissafi","year":"2019","journal-title":"J autoimmunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118053","article-title":"Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation","volume":"14","author":"Cui","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30057","article-title":"A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy","volume":"122","author":"Qi","year":"2016","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.856064","article-title":"The systemic inflammation response index as an independent predictor of survival in breast cancer patients: A retrospective study","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Mol biosciences"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/15593258211064744","article-title":"Systemic inflammation response index as a prognostic marker in cancer patients: A systematic review and meta-analysis of 38 cohorts","volume":"19","author":"Zhou","year":"2021","journal-title":"Dose-Response"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-018-4078-z","article-title":"PRETEXT: radiologic staging system for primary hepatic Malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)","volume":"48","author":"Towbin","year":"2017","journal-title":"Pediatr Radiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-006-0361-5","article-title":"PRETEXT: a revised staging system for primary Malignant liver tumours of childhood developed by the SIOPEL group","volume":"37","author":"Roebuck","year":"2005","journal-title":"Pediatr Radiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2017.03.017","article-title":"Vascular invasion is a prognostic indicator in hepatoblastoma","volume":"52","author":"Shi","year":"2017","journal-title":"J Pediatr Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0529-5807.2019.03.002","article-title":"Specialty Committee of Pathology Futang Research Center of Pediatric Development. Chinese expert group consensus on pathological diagnosis of hepatoblastoma","volume":"48","year":"2019","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0624-8","article-title":"International pediatric liver cancer pathological classification: current trend","volume":"18","author":"Tanaka","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3414\/me14-04-0003","article-title":"Youden\u2019s index and the weight of evidence","volume":"54","author":"Hughes","year":"2015","journal-title":"Methods Inf Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/jci67484","article-title":"Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis","volume":"123","author":"Cools-Lartigue","year":"2013","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6058147","DOI":"10.1155\/2016\/6058147","article-title":"Tumor-associated macrophages and neutrophils in tumor microenvironment","volume":"2016","author":"Kim","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: Receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.08.013","article-title":"CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNF\u03b1","volume":"11","author":"Ren","year":"2012","journal-title":"Cell Stem Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.451","article-title":"Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes\/macrophages through a mechanism that involves Tim-3 and CD40L","volume":"5","author":"Ramello","year":"2014","journal-title":"Cell Death disease"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.11.005","article-title":"Involvement of platelets in tumor cell metastasis","volume":"157","author":"Tesfamariam","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00101","article-title":"Regulation of CD8(+) T cells and antitumor immunity by notch signaling","volume":"9","author":"Tsukumo","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04469-1","article-title":"The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2018-000801","article-title":"Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas","volume":"67","author":"Chen","year":"2019","journal-title":"J Invest Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2506-3","article-title":"Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection","volume":"143","author":"Li","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26010","article-title":"Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma","volume":"42","author":"Valero","year":"2020","journal-title":"Head neck"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27033","article-title":"The prognostic value of adding systemic inflammation response index to Epstein-Barr virus DNA in childhood nasopharyngeal carcinoma: A real-world study","volume":"44","author":"Jin","year":"2022","journal-title":"Head neck"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.904730","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictive markers in hepatoblastoma","volume":"11","author":"Xie","year":"2023","journal-title":"Front pediatrics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30470","article-title":"Neoadjuvant chemotherapy or upfront surgery in hepatoblastoma: A multicenter retrospective study","author":"Tian","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01067","article-title":"Outcome and late complications of hepatoblastomas treated using the Japanese study group for pediatric liver tumor 2 protocol","volume":"38","author":"Hiyama","year":"2020","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22088","article-title":"Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children\u2019s Oncology Group","volume":"53","author":"Meyers","year":"2009","journal-title":"Pediatr Blood cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.11.022","article-title":"Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience","volume":"44","author":"De Ioris","year":"2008","journal-title":"Eur J Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29932","article-title":"A nomogram model to predict prognosis of patients with hepatoblastoma","volume":"69","author":"Ke","year":"2022","journal-title":"Pediatr Blood cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2005.06.006","article-title":"The contribution of transplantation to the treatment of liver tumors in children","volume":"14","author":"Otte","year":"2005","journal-title":"Semin Pediatr surgery"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zs\u00edros","year":"2010","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/mop.0000000000000042","article-title":"Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation","volume":"26","author":"Meyers","year":"2014","journal-title":"Curr Opin pediatrics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25722","article-title":"Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma","volume":"117","author":"Lautz","year":"2011","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000001936","article-title":"and IV hepatoblastoma: extended hepatic resection avoids liver transplantation in selected cases","volume":"266","author":"Fuchs","year":"2017","journal-title":"Ann surgery"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13634","article-title":"Avoiding liver transplantation in post-treatment extent of disease III and IV hepatoblastoma","volume":"60","author":"El-Gendi","year":"2018","journal-title":"Pediatr Int"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.03.004","article-title":"Extensive hepatectomy as an alternative to liver transplant in advanced hepatoblastoma: A new protocol used in a pediatric liver transplantation center","volume":"51","author":"de Freitas Paganoti","year":"2019","journal-title":"Transplant Proc"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/children10020202","article-title":"Long-term outcome following liver transplantation for primary hepatic tumors-A single centre observational study over 40 years","volume":"10","author":"Leiskau","year":"2023","journal-title":"Children (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.sempedsurg.2019.150856","article-title":"Surgical management of locally-advanced and metastatic hepatoblastoma","volume":"28","author":"Lake","year":"2019","journal-title":"Semin Pediatr surgery"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000032022","article-title":"Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial","volume":"101","author":"Tang","year":"2022","journal-title":"Medicine"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-005-2827-5","article-title":"Transarterial chemoembolization in the treatment of hepatoblastoma in children","volume":"16","author":"Vogl","year":"2006","journal-title":"Eur radiology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jpedsurg.2011.10.075","article-title":"Radiofrequency ablation in the treatment of liver tumors in children","volume":"47","author":"van Laarhoven","year":"2012","journal-title":"J Pediatr Surg"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2022.05.022","article-title":"Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children\u2019s Oncology Group Trial, AHEP0731","volume":"57","author":"Vasudevan","year":"2022","journal-title":"J Pediatr Surg"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34014","article-title":"Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children\u2019s Oncology Group study","volume":"128","author":"Katzenstein","year":"2022","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1276175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:22:43Z","timestamp":1697185363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1276175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":71,"alternative-id":["10.3389\/fonc.2023.1276175"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1276175","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"article-number":"1276175"}}